SOURCE: Elsevier Business Intelligence

Elsevier Business Intelligence

December 02, 2010 09:47 ET

'IN3 West' Will Offer Partnering Opportunities for Medtech Companies With Top Investors and Corporate Acquirers in Las Vegas on Feb. 22-24, 2011

41st IN3 Medical Device Partnering Conference Continues With 'New and Improved' Format

LAS VEGAS, NV--(Marketwire - December 2, 2010) - Elsevier Business Intelligence, the medtech industry's leading provider of strategic business intelligence and partnership investment conferences, announced today that it will host 'IN3 West' on Feb. 22-24, 2011, at The Venetian Resort-Hotel-Casino, Las Vegas.

Medical device start-ups continue to face intense competition for a finite amount of available funding. IN3 events offer an unparalleled experience for emerging companies to meet and impress potential investors from many of the top-tier device companies and discerning healthcare investment firms from around the world. Leading venture capital firms and corporate acquirers are expected to attend IN3 West to hear about the latest innovations and investment opportunities from more than 40 emerging medical technology companies seeking funding and/or strategic partnerships.

Equally important, IN3 West will continue with the following 'new and improved' format: 1) Medtech innovators can now present in the same time block as VCs to get in front of the best potential suitor; 2) Conference fees have been reduced and flexible registration options, such as investor pricing, one-day passes and complete hotel/conference packages, are available; 3) More "lessons learned" practical advice sessions on the hottest financing and M&A deals, regulatory updates, and more.

Investment firms and corporate acquirers that have attended IN3 events in the past or who have registered to attend IN3 West 2011 include: Abbot Ventures -- Abingworth Management -- Accuitive Medical Ventures -- Advanced Technology Ventures -- Aisling Capital -- Alloy Ventures -- Apposite Capital -- Arboretum Ventures -- Baird Venture Partners -- Boston Scientific -- Canaan Partners -- Capricorn Venture Partners -- CHL Medical Partners -- Covidien -- Credit Agricole Private Equity -- De Novo Ventures -- Delphi Ventures -- Delta Partners -- Domain Associates -- Earlybird Venture Capital -- Early Stage Partners -- Edmond de Rothschild Investment Partners -- Essex Woodlands Health Ventures -- Forbion Capital Partners -- Fountain Healthcare Partners -- Gilde Healthcare Partners -- Hercules Technology Growth Capital -- HLM Venture Partners -- Hunza Ventures -- Index Ventures -- Interwest Partners -- Kearny Venture Partners -- Life Sciences Partners -- Matignon Investissement & Gestion -- Medtronic -- MPM Capital -- NBGI Ventures -- New Enterprise Associates -- New Leaf Ventures -- Nexus Medical Partners -- Onset Ventures -- Pappas Ventures -- Prism Venture Partners -- PTV Sciences -- RCT BioVentures -- River City Capital Funds -- Safeguard Scientifics -- Seroba-Kernel Life Sciences -- Seventure Partners -- Siemens Venture Capital -- Skyline Ventures -- Smith & Nephew Endoscopy -- Sofimac Partners -- Sofinnova Partners -- Stryker Corporation -- SV Life Sciences -- Synergy Life Science Partners -- Thomas McNerney & Partners -- Trevi Health Ventures -- Versant Ventures -- Vivo Ventures -- Wellington Partners -- Ysios Capital.

Upcoming IN3 events: 1) March 15-16, 2011, IN3 Europe, Le Meridien Montparnasse, Paris; 2) June 21-23, 2011, IN3 East, Boston, The Hyatt Regency. For more information about IN3 events, please contact: Kayleen Kell at +1-949-453-0071, or email K.Kell@Elsevier.com.

About Elsevier Business Intelligence
Elsevier Business Intelligence, an Elsevier company, is a global information supplier providing business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Elsevier Business Intelligence (www.elsevierbi.com) has offices in the U.S. in Bridgewater, N.J.; Norwalk, Conn.; Rockville, Md.; and Irvine, Calif.

About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (www.thelancet.com) and Cell (www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include Sciverse ScienceDirect (www.sciencedirect.com), Sciverse Scopus (www.scopus.com), Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and Nursing Consult (www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (www.scival.com) and MEDai's Pinpoint Review (www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Contact Information